glp-1 drugs and crohn's disease Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, therapeutic potential Oral Crohn's Disease Medications: Effectiveness,

Methods In this open-label, single-center, casecontrol pilot study, patients with IIH (pwIIH) and a body mass index (BMI) of30 kg/m2 were offered to receive a GLP-1-RA (semaglutide, liraglutide) in addition to the usual care weight management (UCWM)

While these agents are not recommended during pregnancy, their use in the preconception, periconception, and postpartum periods is increasing

CU Cancer Center member Bryan Haugen, MD, breaks down the science behind the FDA warning on the GLP-1 weight-loss medications.

Aspiration of gastric contents can still occur despite appropriate preoperative fasting in patients taking GLP-1 agonists

Get the details here